Omnicell (OMCL)
(Delayed Data from NSDQ)
$50.14 USD
-2.32 (-4.42%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $50.16 +0.02 (0.04%) 7:58 PM ET
1-Strong Buy of 5 1
C Value C Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$50.14 USD
-2.32 (-4.42%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $50.16 +0.02 (0.04%) 7:58 PM ET
1-Strong Buy of 5 1
C Value C Growth B Momentum B VGM
Zacks News
ResMed (RMD) Hits a 52-Week High: What's Driving the Stock?
by Zacks Equity Research
ResMed (RMD) gains from impressive performance of its SaaS business.
Here's Why You Should Add Omnicell to Your Portfolio Now
by Zacks Equity Research
Investor confidence in Omnicell (OMCL) is at a high, thanks to solid prospects.
Omnicell-Huron Sign a Pact for Outcome-Based Expert Services
by Zacks Equity Research
Omnicell (OMCL) partners Huron to provide customers with committed expertise.
Worried About Market Downturn? Buy These Low Leverage Stocks
by Zacks Equity Research
Debt is a much cheaper form of financing than equity. Yet the fact that debt carries the burden of interest payments makes it dearer.
Omnicell (OMCL) Partners With Kit Check to Offer Bluesight
by Zacks Equity Research
This partnership will offer Omnicell (OMCL) the state-of-the art technology and medication intelligence needed to ensure accurate delivery of drugs to the right patients.
Omnicell to Feature Upgrades in Medication Management at ASHP
by Zacks Equity Research
Omnicell (OMCL) to showcase innovations in medication management solution portfolio to minimize human errors by care providers.
Zacks.com featured highlights include: Manulife, Gibraltar, Omnicell, SolarEdge and Career Education
by Zacks Equity Research
Zacks.com featured highlights include: Manulife, Gibraltar, Omnicell, SolarEdge and Career Education
Omnicell (OMCL) Rides on Global Expansion, Strategic R&Ds
by Zacks Equity Research
Omnicell's (OMCL) diligent focus on product innovation through R&D is encouraging.
Buy These 5 Low Leverage Stocks to Keep Your Portfolio Safe
by Aparajita Dutta
To safeguard one's portfolio from massive losses, the real challenge for an investor is to determine whether an organization's debt level is sustainable.
SYNH vs. OMCL: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
SYNH vs. OMCL: Which Stock Is the Better Value Option?
Omnicell (OMCL) Beats on Q3 Earnings, Raises '19 EPS View
by Zacks Equity Research
Omnicell (OMCL) continues to see solid segmental contributions in Q3. Expansion of gross and operating margins is a positive too.
Omnicell (OMCL) Q3 Earnings Surpass Estimates
by Zacks Equity Research
Omnicell (OMCL) delivered earnings and revenue surprises of 5.56% and -1.60%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Omnicell (OMCL) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Omnicell (OMCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Omnicell Advances on Global Footing Despite Severe Rivalry
by Zacks Equity Research
Considering the weak penetration level in the international market, which is even less than 1%, Omnicell (OMCL) is rapidly exploring the uncharted overseas markets.
Bright Near-Term Outlook for Medical Info Systems Industry
by Sreyoshi Mukherjee
Growth prospects look bright for the Zacks Medical Info Systems industry, thanks to rising need for curtailing medical expenses and AI.
Omnicell's Autonomous Pharmacy to Boost Medication Management
by Zacks Equity Research
Omnicell (OMCL) aims to combine technology and innovation to enable pharmacists to expand their outreach to patients and improve services.
Omnicell (OMCL) Up 0.4% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Omnicell (OMCL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Hold Onto Omnicell (OMCL) Stock for Now
by Zacks Equity Research
Investor confidence continues to be high on Omnicell's (OMCL) prospects.
Omnicell (OMCL) Beats on Earnings in Q2, Tapers '19 EPS View
by Zacks Equity Research
Omnicell (OMCL) aims at product innovation through R&D.
Omnicell (OMCL) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Omnicell (OMCL) delivered earnings and revenue surprises of 4.69% and 1.98%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Omnicell (OMCL) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Omnicell (OMCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Omnicell (OMCL) Catches Eye: Stock Jumps 8.2%
by Zacks Equity Research
Omnicell (OMCL) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
Here's Why You Should Invest in Omnicell (OMCL) Stock Now
by Zacks Equity Research
Omnicell (OMCL) is boosting investors' optimism, courtesy of consistent positive results.
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Sweta Killa
Sector ETF report for PSCH